Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.
Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Glioblastoma Multiforme Therapeutics market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Glioblastoma Multiforme Therapeutics market. Detailed analysis of key players, along with key growth strategies adopted by Glioblastoma Multiforme Therapeutics industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Merck
Bristol-Myers Squibb
F Hoffmann-La Roche
Eisai
Arbor Pharmaceuticals
By Type:
Temozolomide
Bevacozumab
Carmustine
By End-User:
Hospitals
Clinics
Others
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Glioblastoma Multiforme Therapeutics Market
-
1.3 Market Segment by Type
-
1.3.1 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Temozolomide from 2016 to 2027
-
1.3.2 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Bevacozumab from 2016 to 2027
-
1.3.3 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Carmustine from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Hospitals from 2016 to 2027
-
1.4.2 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Clinics from 2016 to 2027
-
1.4.3 USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Others from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Glioblastoma Multiforme Therapeutics Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Glioblastoma Multiforme Therapeutics by Major Types
-
3.4.1 Market Size and Growth Rate of Temozolomide
-
3.4.2 Market Size and Growth Rate of Bevacozumab
-
3.4.3 Market Size and Growth Rate of Carmustine
4 Segmentation of Glioblastoma Multiforme Therapeutics Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Glioblastoma Multiforme Therapeutics by Major End-Users
-
4.4.1 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Hospitals
-
4.4.2 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Clinics
-
4.4.3 Market Size and Growth Rate of Glioblastoma Multiforme Therapeutics in Others
5 Market Analysis by Regions
-
5.1 USA Glioblastoma Multiforme Therapeutics Production Analysis by Regions
-
5.2 USA Glioblastoma Multiforme Therapeutics Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Glioblastoma Multiforme Therapeutics Landscape Analysis
-
6.1 West USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
6.2 West USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
7 South USA Glioblastoma Multiforme Therapeutics Landscape Analysis
-
7.1 South USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
7.2 South USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
8 Middle West USA Glioblastoma Multiforme Therapeutics Landscape Analysis
-
8.1 Middle West USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
8.2 Middle West USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
9 Northeast USA Glioblastoma Multiforme Therapeutics Landscape Analysis
-
9.1 Northeast USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major Types
-
9.2 Northeast USA Glioblastoma Multiforme Therapeutics Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Merck
-
10.1.1 Merck Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Bristol-Myers Squibb
-
10.2.1 Bristol-Myers Squibb Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 F Hoffmann-La Roche
-
10.3.1 F Hoffmann-La Roche Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Eisai
-
10.4.1 Eisai Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
-
10.5 Arbor Pharmaceuticals
-
10.5.1 Arbor Pharmaceuticals Company Profile and Recent Development
-
10.5.2 Market Performance
-
10.5.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Temozolomide from 2016 to 2027
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Bevacozumab from 2016 to 2027
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Carmustine from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Hospitals from 2016 to 2027
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Clinics from 2016 to 2027
-
Figure USA Glioblastoma Multiforme Therapeutics Market Size and Growth Rate of Others from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Glioblastoma Multiforme Therapeutics Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Glioblastoma Multiforme Therapeutics
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Glioblastoma Multiforme Therapeutics by Different Types from 2016 to 2027
-
Table Consumption Share of Glioblastoma Multiforme Therapeutics by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Temozolomide
-
Figure Market Size and Growth Rate of Bevacozumab
-
Figure Market Size and Growth Rate of Carmustine
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Glioblastoma Multiforme Therapeutics by Different End-Users from 2016 to 2027
-
Table Consumption Share of Glioblastoma Multiforme Therapeutics by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Hospitals
-
Figure Market Size and Growth Rate of Clinics
-
Figure Market Size and Growth Rate of Others
-
Table USA Glioblastoma Multiforme Therapeutics Production by Regions
-
Table USA Glioblastoma Multiforme Therapeutics Production Share by Regions
-
Figure USA Glioblastoma Multiforme Therapeutics Production Share by Regions in 2016
-
Figure USA Glioblastoma Multiforme Therapeutics Production Share by Regions in 2021
-
Figure USA Glioblastoma Multiforme Therapeutics Production Share by Regions in 2027
-
Table USA Glioblastoma Multiforme Therapeutics Consumption by Regions
-
Table USA Glioblastoma Multiforme Therapeutics Consumption Share by Regions
-
Figure USA Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2016
-
Figure USA Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2021
-
Figure USA Glioblastoma Multiforme Therapeutics Consumption Share by Regions in 2027
-
Table West USA Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table West USA Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table South USA Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table South USA Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table South USA Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table South USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure South USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Middle West USA Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Middle West USA Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Middle West USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Northeast USA Glioblastoma Multiforme Therapeutics Consumption by Types from 2016 to 2027
-
Table Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2016
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2021
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by Types in 2027
-
Table Northeast USA Glioblastoma Multiforme Therapeutics Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2016
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2021
-
Figure Northeast USA Glioblastoma Multiforme Therapeutics Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Merck
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck
-
Figure Sales and Growth Rate Analysis of Merck
-
Figure Revenue and Market Share Analysis of Merck
-
Table Product and Service Introduction of Merck
-
Table Company Profile and Development Status of Bristol-Myers Squibb
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb
-
Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb
-
Figure Revenue and Market Share Analysis of Bristol-Myers Squibb
-
Table Product and Service Introduction of Bristol-Myers Squibb
-
Table Company Profile and Development Status of F Hoffmann-La Roche
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of F Hoffmann-La Roche
-
Figure Sales and Growth Rate Analysis of F Hoffmann-La Roche
-
Figure Revenue and Market Share Analysis of F Hoffmann-La Roche
-
Table Product and Service Introduction of F Hoffmann-La Roche
-
Table Company Profile and Development Status of Eisai
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eisai
-
Figure Sales and Growth Rate Analysis of Eisai
-
Figure Revenue and Market Share Analysis of Eisai
-
Table Product and Service Introduction of Eisai
-
Table Company Profile and Development Status of Arbor Pharmaceuticals
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arbor Pharmaceuticals
-
Figure Sales and Growth Rate Analysis of Arbor Pharmaceuticals
-
Figure Revenue and Market Share Analysis of Arbor Pharmaceuticals
-
Table Product and Service Introduction of Arbor Pharmaceuticals
-
